Ipamorelin vs CJC-1295 No DAC

Side-by-side comparison

How they differ in mechanism

Ipamorelin was characterised in late-1990s pharmacology work as a selective growth hormone secretagogue acting at the ghrelin receptor (GHS-R1a) in the pituitary and hypothalamus. The selectivity profile is the central feature of the published characterisation: ipamorelin administration produced growth-hormone release with minimal concurrent release of cortisol, prolactin, ACTH, and aldosterone in the pharmacology studies that established its profile. That clean secretagogue profile distinguished it from earlier-generation GH-releasing peptides that drove non-trivial cortisol and prolactin elevations alongside the GH response.

CJC-1295 No DAC is the modified GHRH(1-29) analogue (sometimes written as MOD GRF 1-29) that retains the first 29 amino acids of growth-hormone-releasing hormone with four substitutions for protease resistance and lacks the drug affinity complex lysine modification present in the DAC-bearing CJC-1295. The compound engages the GHRH receptor on pituitary somatotrophs and drives a pulsatile GH release pattern. The short circulating half-life (approximately 30 minutes in the published research) keeps the release profile pulsatile rather than continuous.

The clinical pharmacology distinction matters in protocol design because the two compounds engage non-overlapping endogenous pathways. Ghrelin-receptor activation and GHRH-receptor activation each drive growth-hormone release independently, and the published work shows that co-administration produces a larger GH-pulse amplitude than either compound alone. That synergy underlies the stacking convention in the research community.

How research has examined each

The ipamorelin literature begins with the late-1990s work that established its selective GHS-R1a engagement and pharmacokinetic profile. Subsequent investigation has characterised the compound across rodent and human pharmacology, with a research focus on the GH-release amplitude and the absence of off-target hormone elevations. Investigators interested in growth-hormone-pulse architecture often cite the ipamorelin work as the cleanest tool compound for isolating ghrelin-receptor effects from GHRH-receptor effects in stacked-design experiments.

The CJC-1295 No DAC literature is concentrated on the GHRH-receptor pharmacology and on the comparison between DAC-bearing and non-DAC variants. The DAC-bearing CJC-1295 has a much longer plasma persistence (extended via covalent attachment to serum albumin through a maleimide-lysine linker) and produces a sustained rather than pulsatile GH release. The non-DAC variant returns to the pulsatile profile that more closely resembles endogenous GHRH-driven release. Researchers interested in pulsatile rather than tonic GH release prefer the No-DAC variant for that reason.

Together, the two literatures provide the mechanistic backing for the most common GH-secretagogue research stack. The published evidence for the stack as a single intervention is limited to combined-administration pharmacology studies rather than long-duration controlled trials, and any researcher designing a stacked-protocol experiment is reading the two primary literatures separately and combining their inferences. No randomised long-duration head-to-head trial of the stack versus either compound alone has appeared in the indexed literature at the time of writing.

Stacking considerations in research contexts

The mechanistic complementarity is the canonical reason laboratory protocols co-administer the two compounds. Ipamorelin engages the ghrelin receptor; CJC-1295 No DAC engages the GHRH receptor; the two pathways converge on pituitary somatotroph GH release through independent intracellular cascades, and the combined administration produces a larger GH-pulse amplitude than either compound alone in the published pharmacology. The Ronin catalog supplies both as separate lyophilised vials so researchers can dose each at their chosen concentration rather than commit to a fixed ratio set by a vendor. The combined-formulation vial is also available for researchers who prefer the canonical fixed-ratio combination.

Sourcing both at Ronin

Both compounds in the Ronin catalog ship as 10 mg lyophilised peptide in glass vials, capped and crimped, with certificate-of-analysis documentation (mass spec + HPLC purity) on the lab-results page. The ipamorelin vial page and the CJC-1295 No DAC vial page hold per-compound spec sheets, reconstitution math, and storage guidance. Both are sold strictly as research-grade reagents for laboratory and bench-research applications.

Frequently asked research questions

References

1. Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998. [PMID 9849822]
2. Hansen BS et al. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues. Drug Metabolism and Disposition, 1999. [PMID 9879640]
3. Hansen TK et al. Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin. Bioorganic & Medicinal Chemistry Letters, 2001. [PMID 11459660]
4. Jetté L et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats. Endocrinology, 2005. [PMID 15817669]
5. Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. Journal of Clinical Endocrinology and Metabolism, 2006. [PMID 16352683]
6. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295. Journal of Clinical Endocrinology and Metabolism, 2006. [PMID 17018654]
7. Bowers CY. Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents. Journal of Pediatric Endocrinology and Metabolism, 1997. [PMID 9238854]